The emergence of artificial intelligence (AI) in the biotech industry has sparked a significant debate about intellectual property rights, especially concerning drug development. A notable example is Insilico Medicine, which utilized its generative AI platform to propose a novel drug for pulmonary fibrosis. In its announcement, the company proudly stated that the molecule was ‘discovered by’ its AI technology. However, when the time came to file a patent, the application listed only human inventors, including CEO Alex Zhavoronkov, casting a spotlight on the complexities of patent law in the age of AI.
This situation underscores a critical issue in intellectual property: the current legal framework requires human inventors for patent applications. A landmark case involving an AI named DABUS was brought forth by attorney Ryan Abbott, who argued that since no human contributed to the invention of a novel food container, the AI should be recognized as the inventor. However, a 2022 ruling by a Washington, DC appeals court determined that patent law defines an inventor as an ‘individual,’ thereby excluding AI from the equation. This ruling highlights the challenges of reconciling the rapid advancements in AI with existing legal definitions.
As AI technology continues to evolve, the question of who qualifies as an inventor could become increasingly complex. With AI systems capable of generating inventions with minimal human input, legal experts like Abbott warn that excluding AI-generated creations from patent protection could stifle innovation in drug development. Currently, the U.S. Patent and Trademark Office adopts a cautious stance, treating AI as a mere tool in the invention process. This uncertainty leaves companies like Insilico Medicine to navigate the intricate landscape of patent law while ensuring that human contributors are properly recognized in the patenting process. As we move forward, it is essential for lawmakers to address these challenges to foster an environment conducive to innovation and scientific progress.
Source: When AI designs a drug, who gets the credit? via MIT Technology Review